Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Document › Details

Osborne Clarke. (3/2/21). "Press Release: Osborne Clarke Advises Oxular on Its £27M Financing".

Organisations Organisation Osborne Clarke (Group)
  Organisation 2 Oxular Ltd.
Products Product legal services
  Product 2 ophthalmic
Index terms Index term Oxular–Osborne Clarke: legal services, 202102 supply service Osborne Clarke has advised Oxular on £27m financing round
  Index term 2 Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion
Persons Person Hayes, Rob (Osborne Clarke 202103 Partner)
  Person 2 Cavanagh, Thomas (Tom) (Precision Ocular 201607 CEO)

International legal practice Osborne Clarke has advised Oxular Limited (Oxular) on its £27 million financing led by Forbion Capital Partners with support from the company’s existing leading investors.

Oxular is developing technology to transform the treatment of retinal disease, including diabetic macular edema and macular degeneration. It is also developing programs for rare and orphan conditions, including ocular cancers and delivery of gene therapies. The investment will fund Phase 2 human clinical studies commencing later this year.

The Osborne Clarke team was led by Thames Valley based corporate Partner Rob Hayes, with support from Associate Magnus Williams and Paralegal Fern Tawera.

Rob said: “It was a pleasure to work with the company on its recent funding. It is undoubtedly a fantastic endorsement of the company’s technology and the management team’s hard work and vision to get the business to this stage.”

Tom Cavanagh, CEO of Oxular, said: “We were very pleased to have Rob and the team at Osborne Clarke to advise us on the transaction. As always, their advice was clear, concise and commercial. We were working to a tight timetable, so having a proactive and very responsive team was extremely valuable to the process.”

Osborne Clarke is recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market.

Connect with one of our experts

Magnus Williams
Associate, UK
M +44 738 454 7017
Email Magnus

Record changed: 2021-03-19


Picture [iito] Plain Stupid Simple 650x80px

More documents for Osborne Clarke (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top